Thermo Electron buys SensorMedics for $70 million
This article was originally published in Clinica
Executive Summary
Thermo Electron has completed the acquisition of SensorMedics, which was announced in April (see Clinica No 700/701, p 13). The deal took the form of a share swap worth around $70 million. This included the issuance of 1.2 million shares of Thermo Electron stock, the option to purchase a further 150,000 and the assumption of certain liabilities.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.